Frontier Pharma Gastric Cancer Early Stage Market Analysis and Treatment, 2021: Hexa Reports
- Submitted by: HexaReport
- Views: 49
- Category: Other
- Date Submitted: 05/15/2016 11:59 PM
- Pages: 5
- Report this Essay
Hexa Reports
Market Research Reports and Insightful Company Profiles
Frontier Pharma Gastric Cancer Early Stage Market Size,
Share, Growth, Treatment, Analysis, Symptoms, Emerging
Trends and Opportunities to 2021
Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
Summary
Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of
the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for
patients with advanced disease, has created a pressing need for improved therapeutic options.
Browse Detail Report With TOC @ http://www.hexareports.com/report/frontier-pharma-gastriccancer-early-stage-pipeline-innovation-shows-shift-towards-targeted-mabs/details
The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy
regimens to complex treatment landscape based on targeted therapies. Recently the market has
witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of
patients.
Hexa Reports
Market Research Reports and Insightful Company Profiles
As the understanding of disease pathophysiology increases, new targets need to be identified and
converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a
gradual shift from generic cytotoxic therapies to more diverse targeted therapies.
Scope
What is the pathophysiology of gastric cancer?
How is gastric cancer diagnosed?
What are the current treatment options?
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer
patients?
What implications will the increased focus on targeted therapies have on the future of gastric
cancer treatment?
What are the most promising first-in-class targets for gastric cancer?
Will the current first-in-class...
Market Research Reports and Insightful Company Profiles
Frontier Pharma Gastric Cancer Early Stage Market Size,
Share, Growth, Treatment, Analysis, Symptoms, Emerging
Trends and Opportunities to 2021
Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
Summary
Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of
the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for
patients with advanced disease, has created a pressing need for improved therapeutic options.
Browse Detail Report With TOC @ http://www.hexareports.com/report/frontier-pharma-gastriccancer-early-stage-pipeline-innovation-shows-shift-towards-targeted-mabs/details
The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy
regimens to complex treatment landscape based on targeted therapies. Recently the market has
witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of
patients.
Hexa Reports
Market Research Reports and Insightful Company Profiles
As the understanding of disease pathophysiology increases, new targets need to be identified and
converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a
gradual shift from generic cytotoxic therapies to more diverse targeted therapies.
Scope
What is the pathophysiology of gastric cancer?
How is gastric cancer diagnosed?
What are the current treatment options?
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer
patients?
What implications will the increased focus on targeted therapies have on the future of gastric
cancer treatment?
What are the most promising first-in-class targets for gastric cancer?
Will the current first-in-class...